Williams Companies, Inc.
—- Market cap
- $90.70B
- Debt
- +$28.02B
- Cash
- —
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 76% equity / 24% debt
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: WMB stock price near parity vs BMRN $74.15 current versus $79.10 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at BMRN's multiple
Implied fair value · at WMB's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple premium
Value edge
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: WMB FY 2025 (ended Dec 31, 2025) · BMRN FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 76% equity / 24% debt
Capital structure 96% equity / 4% debt · EV / Revenue 3.75x · EV / EBITDA 21.37x
WMB carries the larger enterprise value at $118.71B against $12.07B; BMRN trades on the lower EV / Revenue multiple (3.75x vs 9.93x); BMRN on the lower EV / EBITDA (21.37x vs 21.68x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
WILLIAMS COMPANIES, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
BIOMARIN PHARMACEUTICAL INC · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
2.19x
0.08x
Net debt / EBITDA
Leverage against operating earnings
—
-1.43x
Cash and equivalents
Liquid reserves on the balance sheet
—
$1.31B
Total debt
Interest-bearing obligations outstanding
$28.02B
$505.32M
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
KINDER MORGAN, INC.
WMB vs KMI
ONEOK INC /NEW/
WMB vs OKE
Energy Transfer LP
WMB vs ET
ENTERPRISE PRODUCTS PARTNERS L.P.
WMB vs EPD
VERTEX PHARMACEUTICALS INC / MA
WMB vs VRTX
ALNYLAM PHARMACEUTICALS, INC.
WMB vs ALNY
Sarepta Therapeutics, Inc.
WMB vs SRPT
REGENXBIO Inc.
WMB vs RGNX
IONIS PHARMACEUTICALS INC
WMB vs IONS
PTC THERAPEUTICS, INC.
WMB vs PTCT
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.